We are a private oncology-focused company developing a new class of targeted cancer treatments. If you are an accredited investor and would like to learn about current investment opportunities please contact us.
Partner with us
We are seeking development and commercialization partners for SOR-C13. We are also seeking partnerships / research collaborations for our peptide-drug conjugate platform.
SOR-C13 is a first-in-class peptide in development for the targeted treatment of cancer. A multi-center Phase 1 clinical trial is complete. The next clinical trials are planned for early 2018.
We are also developing small peptide-drug conjugates that deliver potent cancer-killing payloads directly to tumors.